Clotting mechanisms in patients with hypertriglyceridemia during therapy with anabolic or progestational drugs.
D000244:Adenosine Diphosphate; D001777:Blood Coagulation / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D004590:Electrophoresis, Paper; D005164:Factor IX / Q000032:analysis; D005165:Factor V / Q000032:analysis; D005167:Factor VII / Q000032:analysis; D005169:Factor VIII / Q000032:analysis; D005170:Factor X / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005500:Follow-Up Studies; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D009640:Norethindrone / Q000009:adverse effects / Q000627:therapeutic use*; D010074:Oxandrolone / Q000009:adverse effects / Q000627:therapeutic use*; D011516:Prothrombin / Q000032:analysis; D011517:Prothrombin Time; D013917:Thrombin / Q000032:analysis; D014280:Triglycerides / Q000097:blood*
D014280:Triglycerides; D000244:Adenosine Diphosphate; D010074:Oxandrolone; D005165:Factor V; D005167:Factor VII; D011516:Prothrombin; D005169:Factor VIII; D005164:Factor IX; D005170:Factor X; D005340:Fibrinogen; D002784:Cholesterol; D013917:Thrombin; D009640:Norethindrone